You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 8,318,169


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,318,169
Title:Sustained release drug delivery systems comprising a water soluble therapeutic agent and a release modifier
Abstract: A biocompatible, sustained release intraocular drug delivery system comprising a protein or polynucleotide therapeutic agent, a polymeric carrier for the therapeutic agent and a long chain fatty alcohol release modifier. The biocompatible, sustained release intraocular drug delivery system can be used to treat an ocular condition.
Inventor(s): Trogden; John T. (Anaheim, CA), Lyons; Robert T. (Laguna Hills, CA)
Assignee: Allergen, Inc. (Irvine, CA)
Application Number:13/230,355
Patent Claims:1. An extruded biodegradable intraocular implant consisting of: a) about 70-85% by weight of a biodegradable polymeric carrier, wherein the biodegradable polymeric carrier is a poly-lactide-co-glycolide (PLGA); b) about 10-20% by weight of a water soluble therapeutic agent; and c) about 5-10% by weight of a saturated straight chain alcohol 16 to 26 carbon atoms in length; wherein the therapeutic agent is selected from the group consisting of peptides, proteins, antibodies, and antibody fragments; and wherein a therapeutically effective amount of the therapeutic agent is released from the biodegradable intraocular implant for at least one week after the intraocular implant is placed in the eye.

2. The biodegradable intraocular implant of claim 1, wherein the water soluble therapeutic agent is adalimumab.

3. The biodegradable intraocular implant of claim 1, wherein said saturated straight chain alcohol is selected from the group consisting of 1-hexadecanol, 1-octadecanol, and 1-eicosanol.

4. The biodegradable intraocular implant of claim 3, wherein said saturated straight chain alcohol is 1-eicosanol.

5. The biodegradable intraocular implant of claim 1, wherein the therapeutic agent is an antibody.

6. The biodegradable intraocular implant of claim 5, wherein the antibody is an anti-VEGF antibody.

Details for Patent 8,318,169

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Abbvie Inc. HUMIRA adalimumab Injection 125057 12/31/2002 ⤷  Try a Trial 2026-11-03
Abbvie Inc. HUMIRA adalimumab Injection 125057 02/21/2008 ⤷  Try a Trial 2026-11-03
Abbvie Inc. HUMIRA adalimumab Injection 125057 04/24/2013 ⤷  Try a Trial 2026-11-03
Abbvie Inc. HUMIRA adalimumab Injection 125057 09/23/2014 ⤷  Try a Trial 2026-11-03
Abbvie Inc. HUMIRA adalimumab Injection 125057 11/23/2015 ⤷  Try a Trial 2026-11-03
Abbvie Inc. HUMIRA adalimumab Injection 125057 03/09/2016 ⤷  Try a Trial 2026-11-03
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.